At Praxis, we are committed to setting very ambitious goals because we understand the urgency of our work on behalf of patients. Listen to Claudio Lavareda Santos, Senior Vice President of Global Medical Affairs, as he talks about what it takes to push beyond comfort zones in order to achieve amazing results.
Praxis Precision Medicines, Inc.
Biotechnology Research
Boston, MA 9,749 followers
The era of genetic neuroscience has arrived
About us
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for rare and more prevalent neurological disorders. We share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain.
- Website
-
http://www.praxismedicines.com
External link for Praxis Precision Medicines, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Public Company
Locations
-
Primary
99 High Street
30th Floor
Boston, MA 02110, US
Employees at Praxis Precision Medicines, Inc.
-
Claudio Lavareda Santos
Senior Global Medical Affairs Leader | Multinational Biopharmaceutical | Rare Diseases
-
Tim Kelly
Chief Financial Officer at Praxis Precision Medicines, Inc.
-
Alex La Croix
Biotechnology leader with experience in commercial, business development, and clinical development/regulatory strategy
-
Brian Pfister
Updates
-
Thank you to all who stopped by our booth or a Praxis presentation at the International Parkinson and Movement Disorder Society #MDSCongress! Our participation highlighted our journey to develop a new #EssentialTremor therapy and our innovative Essential3 registrational program. #ICYMI check out our presentation and access the latest updates and resources related to our #EssentialTremor program: https://bit.ly/4eAY1fS
-
For people worried about having to stop working due to essential tremor, learn about an ET research study now enrolling. https://bit.ly/47i6QqF #clinicaltrial #essentialtremor #MoreThanTremor #Essential3
-
We are proud to be presenting at the International Parkinson and Movement Disorder Society #MDSCongress taking place Sept 27 - Oct 1! Mark your calendars for our presentations taking place Saturday and Sunday and stop by booth #1008 to meet our team and learn more about our journey to develop a new #EssentialTremor therapy.
-
Praxis was thrilled to host the first-ever DEEP Dive Day on Developmental Epileptic Encephalopathies yesterday in Boston, bringing together global leaders and an audience of nearly 300 people, both in person and via live stream. A big thank you to all the presenters for being part of this event and for the inspiring work you do to help advance new treatments for these communities. #SCN2A #SCN8A #KCNT1 #PCDH19 #SYNGAP1 #DAREFORMORE
-
+10
-
❗Final Countdown❗ Join Praxis for our inaugural DEEP Dive (Developmental and Epileptic Encephalopathies) event, where you'll hear from global leaders in the pediatric genetic epilepsy community, including clinical investigators and patient advocacy leaders, about the most recent developments and therapies. 📅 The event will be held in person on September 24th at 7:30 a.m. EDT and live-streamed from Boston. 🔗 Register here: https://lnkd.in/eK8Ya4Wy
-
Learn about a research study evaluating an investigational drug to see if it may help manage ET symptoms and benefit future patients.https://bit.ly/47i6QqF #clinicaltrial #essentialtremor #MoreThanTremor #Essential3
-
❗ Join Praxis for our inaugural DEEP Dive (Developmental and Epileptic Encephalopathies) event, where you'll hear from global leaders in the pediatric genetic epilepsy community, including clinical investigators and patient advocacy leaders, about the most recent developments and therapies. 📅 This event will be held in person on September 24th at 7:30 a.m. EDT and live-streamed from Boston. 🔗 Register here: https://lnkd.in/eK8Ya4Wy
-
If simple daily tasks require adjustments due to essential tremor, consider an at-home research study. https://bit.ly/47i6QqF #clinicaltrial #essentialtremor #MoreThanTremor #Essential3
-
Thank you to all who stopped by our booth or a Praxis presentation at #EEC2024! Our participation highlighted our commitment to advancing therapies for CNS disorders and included updates across our broad portfolio of #epilepsy assets. Visit our website for the latest updates and resources related to our #epilepsy programs, ongoing trials, and more: https://lnkd.in/gv_2g8c5